Invention Application
- Patent Title: COMBINATION THERAPY USING ANTIBODY TO HUMAN SIGLEC-9 AND ANTIBODY TO HUMAN NKG2A FOR TREATING CANCER
-
Application No.: US17933133Application Date: 2022-09-19
-
Publication No.: US20230085847A1Publication Date: 2023-03-23
- Inventor: STÉPHANIE CORNEN , BENJAMIN ROSSI , NICOLAI WAGTMANN
- Applicant: INNATE PHARMA
- Applicant Address: FR MARSEILLE
- Assignee: INNATE PHARMA
- Current Assignee: INNATE PHARMA
- Current Assignee Address: FR MARSEILLE
- Main IPC: C07K16/28
- IPC: C07K16/28 ; A61P35/00 ; A61K39/00
Abstract:
This invention relates to agents that bind human Siglecs having inhibitory activity in immune cells, and that neutralize the inhibitory activity of such Siglec. Such agents can be used for the treatment of cancers.
Information query
